Trial Profile

Phase 3 pivotal trial of ARV 110 in the patients with AR T878/H875 tumor mutations

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 15 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bavdegalutamide (Primary)
Indications Prostate cancer
Focus Registrational; Therapeutic Use
Sponsors Arvinas

Most Recent Events

08 Nov 2022 According to a Arvinas media release, Confirm final dose selection and secure final health authority feedback on trial protocol is expected in 1H 2023.
04 Aug 2022 According to a Arvinas media release, the company plans to initiate a Phase 3 trial in metastatic castration-resistant prostate cancer, or mCRPC, for patients with AR T878/H875 tumor mutations in 2H 2023.
28 Feb 2022 According to a Arvinas media release, this trial is expected to begin by year end-2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com